scholarly journals Development and validation of a clinical instrument to predict risk of an adverse drug reactions in hospitalized patients

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243714
Author(s):  
Sara Iasmin Vieira Cunha Lima ◽  
Rand Randall Martins ◽  
Valdjane Saldanha ◽  
Vivian Nogueira Silbiger ◽  
Isabelle Cristina Clemente dos Santos ◽  
...  

Objective Development and internal validation of a clinical tool for assessment of the risk of adverse drug reactions (ADR) in hospitalized patients. Methodology Nested case-control study in an open cohort of all patients admitted to a general hospital. Cases of ADR were matched to two controls. Eighty four patient variables collected at the time of the ADR were analyzed by conditional logistic regression. Multivariate logistic regression with clustering of cases in a random sample of 2/3 of the cases and respective controls, with baseline odds-ratio corrected with an estimate of ADR incidence, was used to obtain regression coefficients for each risk factor and to develop a risk score. The clinical tool was validated in the remaining 1/3 observations. The study was approved by the institution’s research ethics committee. Results In the 8060 hospitalized patients, ADR occurred in 343 (5.31%), who were matched to 686 controls. Fourteen variables were identified as independent risk factors of ADR: female, past history of ADR, heart rate ≥72 bpm, systolic blood pressure≥148 mmHg, diastolic blood pressure <79 mmHg, diabetes mellitus, serum urea ≥ 67 mg/dL, serum sodium ≥141 mmol/L, serum potassium ≥4.9 mmol/L, main diagnosis of neoplasia, prescription of ≥3 ATC class B drugs, prescription of ATC class R drugs, prescription of intravenous drugs and ≥ 6 oral drugs. In the validation sample, the ADR risk tool based on those variables showed sensitivity 61%, specificity 73% and area under the ROC curve 0.73. Conclusion We report a clinical tool for ADR risk stratification in patients hospitalized in general wards based on 14 variables.

2005 ◽  
Vol 14 (7) ◽  
pp. 501-506 ◽  
Author(s):  
K. Gholami ◽  
S. Parsa ◽  
G. Shalviri ◽  
M. Sharifzadeh ◽  
N. Assasi

2018 ◽  
Vol 9 ◽  
Author(s):  
Claudia Giardina ◽  
Paola M. Cutroneo ◽  
Eleonora Mocciaro ◽  
Giuseppina T. Russo ◽  
Giuseppe Mandraffino ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Mayuko Sugioka ◽  
Tomoya Tachi ◽  
Takashi Mizui ◽  
Aisa Koyama ◽  
Azusa Murayama ◽  
...  

AbstractIn pediatric individuals, polypharmacy would increase the prevalence of adverse drug reactions (ADRs). However, there is no report on the ADR increase adjusted for the influence of concomitant disease types. We conducted a retrospective study in pediatric patients to determine whether polypharmacy is a risk factor for ADR development, after the adjustment. Patients aged 1–14 years on medication who visited Gifu Municipal Hospital (Gifu, Japan) were included. We evaluated patient characteristics, ADR causality, ADR classification and severity, and ADR-causing drugs. We examined the association between ADR prevalence and number of drugs used. We performed multiple logistic regression analyses to investigate risk factors for ADR development. Of 1330 patients, 3.5% sought medical attention for ADRs. ADR causality was most often assessed as “possible,” with gastrointestinal ADRs being the most common. Grade 1 ADRs were the most and antibiotics were the most common suspected ADR-inducing drug. The multiple logistic regression analysis showed that ≥ 2 or ≥ 4 drug use, neoplasms, mental and behavioral disorders, and circulatory system diseases significantly increased ADR prevalence. Polypharmacy increased the prevalence of ADR resulting in hospital visits in children, after adjusting for the influence of disease types. Therefore, proactive polypharmacy control measures are necessary for children.


Drugs & Aging ◽  
2011 ◽  
Vol 28 (5) ◽  
pp. 379-390 ◽  
Author(s):  
Andrea Corsonello ◽  
Claudio Pedone ◽  
Fabrizia Lattanzio ◽  
Graziano Onder ◽  
Raffaele Antonelli Incalzi

Sign in / Sign up

Export Citation Format

Share Document